Pentixapharm Acquires Target Discovery Business of Glycotope

Pentixapharm AG, a clinical-stage biotech firm, has agreed to acquire Glycotope GmbH's target discovery business. This acquisition, effective July 1, 2024, includes preclinical antibodies, laboratories, cell banks, a tumor target database, equipment, patents, and licenses. Additionally, Pentixapharm will integrate a team of 40 experienced professionals.

The acquisition will expand Pentixapharm’s Intellectual Property portfolio beyond the CXCR4 receptor, doubling the development pipeline. Glycotope's target discovery will enhance Pentixapharm's diagnostic and therapeutic capabilities. The deal also paves the way for Pentixapharm’s separation from mother company Eckert & Ziegler SE and its planned listing on the Frankfurt Stock Exchange.

Leadership changes will follow, with current CEO Hakim Bouterfa transitioning to the Supervisory Board and Dirk Pleimes, the Chief Medical Officer, succeeding him. Patrik Kehler becomes the Chief Scientific Officer, and Henner Kollenberg takes over administrative and business development roles.